COYA
Coya Therapeutics, Inc. Common Stock
NASDAQ: COYA · HEALTHCARE · BIOTECHNOLOGY
$4.07
-4.46% today
Updated 2026-04-29
Market cap
$95.47M
P/E ratio
—
P/S ratio
12.02x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$4 – $8
Volume
0.1M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B7.8
Quality
B+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
3.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$15.64
+284.28%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.46 — safe zone
+ Revenue growth 202,769.00% QoQ
Risks
- Thin margins at -267.10%
- Negative free cash flow $-1.01M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $6.00M | $3.55M | $7.95M | $7.95M |
| Net income | $-12.24M | $-7.99M | $-14.88M | $-21.23M | $-5.71M |
| EPS | — | — | — | — | $-1.27 |
| Free cash flow | $-7.24M | $-11.19M | $-10.29M | $-10.74M | $-1.01M |
| Profit margin | — | -133.08% | -418.70% | -267.14% | -267.10% |
Peer comparison
Smart narrative
Coya Therapeutics, Inc. Common Stock trades at $4.07. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 3.46, it sits in the safe zone. TTM revenue stands at $7.95M. with profit margins at -267.10%.
Frequently asked questions
What is Coya Therapeutics, Inc. Common Stock's stock price?
Coya Therapeutics, Inc. Common Stock (COYA) trades at $4.07.
Is Coya Therapeutics, Inc. Common Stock overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell).
What is the price target of Coya Therapeutics, Inc. Common Stock (COYA)?
The analyst target price is $15.64, representing +284.3% upside from the current price of $4.07.
What is Coya Therapeutics, Inc. Common Stock's revenue?
TTM revenue is $7.95M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
3.46 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.02x
ROE-51.40%
Beta0.52
50D MA$4.48
200D MA$5.48
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—